Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.39 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | UBE2M | P61081 | 1/20 | 0.30 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28982266 | 1.00 | BACE1 (0.39) | BACE1PSDL3MBTL3L3MBTL1POLB | |
| SCHEMBL21707918 | 1.00 | BACE1 (0.39) | BACE1PSDL3MBTL3L3MBTL1POLB | |
| SCHEMBL8163166 | 0.83 | BRD4 (0.43) | L3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL21037265 | 0.83 | BRD4 (0.43) | L3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL29963891 | 0.83 | BRD4 (0.43) | L3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL21379804 | 0.83 | BRD4 (0.43) | L3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL22054365 | 0.83 | BRD4 (0.43) | L3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL28982269 | 0.83 | BRD4 (0.43) | L3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL30641160 | 0.83 | BRD4 (0.43) | L3MBTL1POLBLMNAALDH1A1 | |
| SCHEMBL22118294 | 0.79 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1MGLLRBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134710-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2020-02-12 | — | — | EP | claimed |
| US-8779139-B2 | Substituted 2,3,4,4A,5,9B-hexahydro-1H-pyrido[4,3-B]indole derivatives synthesis and uses thereof | INTRA-CELLULAR THERAPIES, INC. | 2014-07-15 | — | — | US | claimed |
| US-20130046097-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2013-02-21 | — | — | US | claimed |
| US-8309722-B2 | Substituted heterocycle gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-11-13 | — | — | US | claimed |
| EP-3897643-B1 | A PYRIDOPYRROLOQUINOXALINE COMPOUND AND ITS MEDICAL USE | INTRA CELLULAR THERAPIES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023069880-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220064166-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20220056031-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220048910-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3946345-A1 | METHODS OF TREATING NEUROPATHIC PAIN | Intra-Cellular Therapies, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-9315504-B2 | Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140364609-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8779139-B2 | Substituted 2,3,4,4A,5,9B-hexahydro-1H-pyrido[4,3-B]indole derivatives synthesis and uses thereof | INTRA-CELLULAR THERAPIES, INC. | 2014-07-15 | — | — | US | disclosed |
| US-20130046097-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2013-02-21 | — | — | US | disclosed |
| US-8309722-B2 | Substituted heterocycle gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRACELLULAR THERAPIES, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2134710-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112280-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056031-A1 | ORGANIC COMPOUNDS | HTR2C, HTR2A, HTR1A | BACE1 1548/4885PSD 1288/4885L3MBTL3 4118/4885 |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, CBR3 | BACE1 839/4885PSD 2921/4885L3MBTL3 3498/4885 |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | BACE1 947/4885PSD 2233/4885L3MBTL3 3429/4885 |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | BACE1 1373/4885PSD 1569/4885L3MBTL3 3786/4885 |
| US-20140364609-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | BACE1 877/4885PSD 2397/4885L3MBTL3 3490/4885 |
| US-20130046097-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, CBR3 | BACE1 839/4885PSD 2921/4885L3MBTL3 3498/4885 |
| US-20220048910-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | BACE1 952/4885PSD 1167/4885L3MBTL3 2827/4885 |
| US-20220064166-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | BACE1 947/4885PSD 2233/4885L3MBTL3 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.